Patients Supported with Impella 5.5 Percutaneous LVAD may have higher hemolysis and need for blood products: Study Dr Monish Raut12 April 2025 8:30 AM ISTRecent study evaluated hemolysis in patients supported with the Impella 5.5 percutaneous left ventricular assist device in a single-center experience....
Rare case of cobalamin c deficiency presenting with nephrotic syndrome, malignant hypertension and hemolytic anemia: A report Dr Riya Dave14 July 2024 9:15 PM ISTResearchers have identified that a rare metabolic disorder of cobalamin C (cblC) defect can manifest as nephrotic syndrome in infants. This further...
Intravenous Immunoglobulin-induced Hemolysis Dr. Nandita Mohan28 Oct 2022 10:00 AM ISTIt is known that intravenous immunoglobulin is an established treatment for many immune-mediated disorders. A study Shows about presents case...
New rechristened rectangular Amplatzer PVL plug for transcatheter closure Dr. Nandita Mohan27 July 2022 9:00 AM ISTIn a recent study published in IHJ researchers tried a Single-center experience of transcatheter closure of mitral and aortic Paravalvular leaks...
COVID-19 vaccines may increase hemolysis risk in PNH patients: Study Dr Satabdi Saha26 Jun 2021 7:45 AM ISTAccording to recent research reports published in Blood ,Patients with paroxysmal nocturnal hemoglobinuria (PNH) who receive vaccination for...
Sutimlimab increases Hb levels, prevents hemolysis in cold agglutinin disease: NEJM Medha Baranwal8 April 2021 7:45 AM ISTDelhi: Selective upstream inhibition of activity in the classic complement pathway rapidly reduced fatigue, increased hemoglobin levels, and halted...
HbA1c lowering by Sulfasalazine in diabetes due to haemolytic effects: Study MD Bureau15 Dec 2020 11:44 AM ISTSulfasalazine is associated with HbA1c lowering by hematological changes consistent with haemolysis and not by glycemia, suggests a study published in...
Sanofi gets USFDA priority review for sutimlimab for Hemolysis Ruchika Sharma17 May 2020 11:00 AM ISTParis: The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi's Biologics License Application (BLA) for sutimlimab for the...
